Terry Gernsheimer is a Hematology physician affiliated with University of Washington. OpenAlex indexes 110 publications with 13,343 citations (h-index 35); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Seattle Cancer Care Alliance
825 Eastlake Avenue East
Seattle, WA 98109
Telephone
206-288-1012Registry record last updated 31 Mar 2009.
Clinical trials
- Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Sponsor: Cellphire Therapeutics, Inc.
- American Trial Using Tranexamic Acid in Thrombocytopenia
Sponsor: University of Washington
- Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets
Sponsor: U.S. Army Medical Research and Development Command
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20256 payments
- SOBI, INCProgram year20245 payments$17,644openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year20244 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
100%Thrombopoietin Receptor Agonist100%Promacta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2015–2019 per NIH RePORTER. The latest:
- American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT)
University of Washington
FY2019$885,149U01HL122894 - American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT)
University of Washington
FY2018$1,190,601U01HL122894 - American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT)
University of Washington
FY2017$1,502,614U01HL122894
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Rilzabrutinib <i>versus</i> placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study
Therapeutic Advances in Hematology
2023 - Thrombocytopenia following Pfizer and Moderna <scp>SARS‐CoV</scp>‐2 vaccination
American Journal of Hematology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Neal Futran, MD, DMD
University of Washington
Elizabeth Swisher
University of Washington
David Tirschwell
University of Washington
Elaine Peskind, MD
University of Washington
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”